GlobeNewswire Inc.··NanobiotixNanobiotix's Lung Cancer Drug Shows Striking 85.7% Response Rate in Phase 2 Trial
Nanobiotix reports promising Phase 2 data for JNJ-1900 (NBTXR3) in inoperable lung cancer, achieving 85.7% overall response rate versus standard care's <5% complete response rate.
JNJNBTXPhase 2 clinical trialimmunotherapy